Skip to content

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00149175
Enrollment
2256
Registered
2005-09-08
Start date
2002-12-01
Completion date
2020-12-31
Last updated
2026-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's Disease, Dementia, Neurodegenerative Disorders

Keywords

Alzheimer's disease, Dementia, Phenotype-genotype correlations, Candidate genes, Related disorders

Brief summary

Patients with different types of dementia will be recruited and evaluated in national hospital departments for their usual neurological follow-ups. A blood sample will be proposed in the field of this research project, and the biological material will be stored at the DNA and Cell Bank of Institut de Fédératif Recherche (IFR) of Neurosciences (Pitié-Salpêtrière Hospital, Paris). The clinical research network is already set up for Alzheimer's disease and frontotemporal dementias, which permits an evaluation according to a clinical standardized protocol. Among these disorders, a monogenic sub-group has been identified. In Alzheimer's disease, it is associated with the APP, PSEN1 and PSEN2 genes, which account only for 75% of the familial forms with early onset. In frontotemporal dementias, the tau gene mutations account only for 10% of the cases with an autosomal dominant inheritance. The identification of familial forms with a genetic inquiry in the relatives is essential for a greater knowledge of the molecular bases of forms not caused by the known genes, using linkage approaches and candidate gene analysis. The familial forms are also useful for identifying the modifier genes. In the multifactorial forms, the aim is to assemble a wide cohort of patients and controls matched for localizing and identifying susceptibility genetic factors. The strategies will use a candidate gene approach, and in the near future, studies of single nucleotide polymorphisms (SNPs) spread out in the whole genome. Meanwhile, similar approaches, particularly with candidate genes, could be used for identifying predictive factors of tolerance and response to the treatment. Finally, correlations will be performed with seric markers according to each kind of dementia. Specialized clinical teams in diagnosis and follow-up in dementias are assembled for this project, and in the study of neurological disorders of genetic origin.

Interventions

OTHERBlood sampling, skin biopsy

Blood sampling, skin biopsy in the field of the medical follow-up

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV
Aventis Pharmaceuticals
CollaboratorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients presenting with a neurodegenerative disorder with cognitive impairment controls (without signs of the disease), matched with sex and age with the patients * Relatives for the familial cases

Exclusion criteria

* Pregnant women * Minors * Persons refusing to sign the informed consent

Design outcomes

Primary

MeasureTime frameDescription
Bulding up a collection of blood samplesOver an 11 years periodSetting up genotype-phenotype correlations for patients with various neurodegenerative diseases

Countries

France

Contacts

PRINCIPAL_INVESTIGATORAlexis Brice, MD

Assistance Publique - Hôpitaux de Paris, University Paris 6

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 21, 2026